Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.

Our data clearly show that it is feasible and safe to implement stepwise acceleration of nivolumab and pembrolizumab administration to a 10-minute infusion time,” the researchers wrote.

A vomiting-free ward protocol significantly reduced the effects of nausea and vomiting on QOL, anxiety, and depression, in patients with gynecologic cancers receiving chemotherapy.

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.